Mao, X.; Cai, Y.; Long, S.; Perez-Losada, J.; Mao, J.-H.; Chang, H. Pan-Cancer Evaluation of Clinical Value of Mitotic Network Activity Index (MNAI) and Its Predictive Value for Immunotherapy. Frontiers in Oncology 2023, 13, doi:10.3389/fonc.2023.1178568.
Mao, X.; Cai, Y.; Long, S.; Perez-Losada, J.; Mao, J.-H.; Chang, H. Pan-Cancer Evaluation of Clinical Value of Mitotic Network Activity Index (MNAI) and Its Predictive Value for Immunotherapy. Frontiers in Oncology 2023, 13, doi:10.3389/fonc.2023.1178568.
Mao, X.; Cai, Y.; Long, S.; Perez-Losada, J.; Mao, J.-H.; Chang, H. Pan-Cancer Evaluation of Clinical Value of Mitotic Network Activity Index (MNAI) and Its Predictive Value for Immunotherapy. Frontiers in Oncology 2023, 13, doi:10.3389/fonc.2023.1178568.
Mao, X.; Cai, Y.; Long, S.; Perez-Losada, J.; Mao, J.-H.; Chang, H. Pan-Cancer Evaluation of Clinical Value of Mitotic Network Activity Index (MNAI) and Its Predictive Value for Immunotherapy. Frontiers in Oncology 2023, 13, doi:10.3389/fonc.2023.1178568.
Abstract
Increased mitotic activity is associated with the genesis and aggressiveness of many cancers. To assess the clinical value of mitotic activity as prognostic biomarker, we performed a pan-cancer study on the mitotic network activity index (MNAI) constructed based on 54-gene mitotic apparatus network. Our pan-cancer assessment on TCGA (33 tumor types, 10,061 patients) and validation on other publicly available cohorts (23 tumor types, 9,209 patients) confirmed the significant association of MNAI with overall survival, progression-free survival and other prognostic endpoints in multiple cancer types, including Lower-Grade Gliomas (LGG), Breast Invasive Carcinoma (BRCA) and many others. We also showed significant association of MNAI with genetic instability, which provides a biological explanation of its prognostic impact at pan-cancer landscape. Futhermore, we found that patients with high MNAI benefit more from anti-PD-1 and Anti-CTLA-4 treatment. In addition, we demonstrated on LGG and BRCA that the multimodal integration of MNAI and the AI-empowerd Cellular Morphometric Subtypes (CMS) significantly improved the predictive power of prognosis compared to MNAI and CMS alone. Our results suggest that MNAI can be used as a potential prognostic biomarker for different tumor types toward different clinical endpoints, and multimodal integration of MNAI and CMS exceeds individual biomarker for precision prognosis.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
